Detalhe da pesquisa
1.
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis. / Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
Gastroenterol Hepatol
; 47(5): 522-552, 2024 May.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38311005
2.
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study). / Impacto de la mesalazina en la respuesta a la vacunación contra la COVID-19 en pacientes con enfermedad inflamatoria intestinal. Resultados de un estudio prospectivo multicéntrico de GETECCU (VACOVEII).
Gastroenterol Hepatol
; 2024 Jan 12.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38219960
3.
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease. / Documento de posicionamiento. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre sexualidad y enfermedad inflamatoria intestinal.
Gastroenterol Hepatol
; 2024 Jan 11.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38218430
4.
Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus. / Optimización del tratamiento de la colitis ulcerosa leve a moderada: Consenso Delphi CU-Forum.
Gastroenterol Hepatol
; 46(10): 784-794, 2023 Dec.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36803681
5.
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).
Gastroenterol Hepatol
; 2023 Nov 23.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38007154
6.
Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration.
Rev Esp Enferm Dig
; 114(6): 358, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35105150
7.
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
J Crohns Colitis
; 17(1): 83-91, 2023 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913456
8.
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Aliment Pharmacol Ther
; 58(1): 60-70, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37089065
9.
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
Inflamm Bowel Dis
; 28(11): 1725-1736, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35166347
10.
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.
J Clin Med
; 11(15)2022 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35956133
11.
Dysbiotic microbiota interactions in Crohn's disease.
Gut Microbes
; 13(1): 1949096, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34313550
12.
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
J Crohns Colitis
; 15(1): 35-42, 2021 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969471
13.
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study.
Expert Rev Gastroenterol Hepatol
; 13(8): 807-813, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31203691
14.
Multiple fixed-drug eruption and diarrhea with ticlopidine.
Ann Pharmacother
; 36(2): 344-5, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11847960